State 340B Contract-Pharmacy Anti-Interference Laws Survive Preemption and Constitutional Challenges; State-Party Presumption Defeats Redundant Intervention

Case: Pharm Research and Mfr v. Murrill (consolidated with manufacturers’ appeals)
Court: United States Court of Appeals for the Fifth Circuit
Date: February 9, 2026

1) Introduction

These consolidated appeals arise from Louisiana’s response to manufacturer restrictions on the use of “contract pharmacies” within the federal Section 340B Drug Pricing Program (42 U.S.C. § 256b). The 340B program requires participating manufacturers to sell covered outpatient drugs to specified safety-net providers (“covered entities”) at or below a statutory ceiling price, aiming to stretch scarce healthcare dollars for low-income and rural patients.

Because many covered entities cannot operate in-house pharmacies, they frequently contract with independent pharmacies to dispense 340B-purchased drugs. Manufacturers increasingly imposed policies limiting deliveries to contract pharmacies, prompting several states to enact “anti-interference” statutes. Louisiana’s Act 358 bars manufacturers and distributors from “deny[ing], restrict[ing], prohibit[ing], or otherwise interfer[ing]” with a covered entity’s acquisition of 340B drugs and delivery to contract pharmacies, and it treats violations as violations of Louisiana’s Unfair Trade Practices and Consumer Protection Law.

Plaintiffs—AbbVie and affiliates, AstraZeneca, and the trade association Pharmaceutical Research and Manufacturers of America (PhRMA)—sued Louisiana’s Attorney General, Liz Murrill, seeking declaratory and injunctive relief. They asserted (i) federal preemption (field/conflict/obstacle) and also (ii) constitutional claims: AbbVie (Takings Clause; vagueness), AstraZeneca (Contracts Clause), PhRMA (vagueness). The district court granted summary judgment for Louisiana across the board. The Fifth Circuit affirmed on the merits, but reversed intervention granted to the Louisiana Primary Care Association (LPCA) in AbbVie’s case.

2) Summary of the Opinion

3) Analysis

A. Precedents Cited (and How They Drive the Outcome)

1. The 340B program’s structure and enforcement: Astra USA, Inc. v. Santa Clara Cnty.

The court relies on Astra USA, Inc. v. Santa Clara Cnty. to describe the 340B “straightforward bargain” and the role of HRSA and PPAs. Astra matters because it underscores that PPAs “recite” statutory obligations and that Congress vested compliance oversight in HHS—facts that later shape both the Contracts Clause discussion (PPAs are uniform statutory instruments rather than negotiated delivery contracts) and the preemption analysis (federal law is detailed in some respects but silent in others).

2. The contract-pharmacy controversy and federal “silence”: Sanofi Aventis U.S. LLC v. U.S. Dep't of Health & Hum. Servs. and Novartis Pharms. Corp. v. Johnson

To frame the modern dispute, the opinion cites Sanofi Aventis U.S. LLC v. U.S. Dep't of Health & Hum. Servs. and Novartis Pharms. Corp. v. Johnson, which rejected HHS’s attempt (via advisory opinion) to require delivery to an unlimited number of contract pharmacies. The Fifth Circuit uses these cases for a precise proposition: § 340B is “silent” about delivery conditions and contract-pharmacy logistics. That silence becomes the linchpin for rejecting field and conflict/obstacle preemption of state “anti-interference” laws.

3. The controlling Fifth Circuit precedent: AbbVie, Inc. v. Fitch

The decisive move is the court’s statement that AbbVie, Inc. v. Fitch “controls here.” In Fitch, the Fifth Circuit upheld a materially indistinguishable Mississippi statute against the same suite of preemption and Takings Clause challenges. This opinion treats Fitch as binding not only for its conclusions but for its framing: § 340B regulates price ceilings, eligibility, anti-diversion/duplicate-discount rules, audits, and enforcement mechanisms, but does not regulate distribution to patients or the role of pharmacies in that distribution. Louisiana’s Act 358 is placed squarely in that unregulated space.

4. Sister-circuit reinforcement: Pharm. Rsch. & Mfrs. of Am. v. McClain

The court cites Pharm. Rsch. & Mfrs. of Am. v. McClain (Eighth Circuit) for the complementary conclusion that state contract-pharmacy protections do not “set or enforce discount pricing,” and that Congress’s silence about pharmacies in § 340B supports a role for state law. This bolsters the Fifth Circuit’s obstacle-preemption rejection (Act 358 regulates conduct/delivery interference, not pricing).

5. Jurisdiction and the preemption “cause of action” framing: Elam v. Kansas City Southern Railway Co., Planned Parenthood of Hou. & Se. Tex. v. Sanchez, and Shaw v. Delta Air Lines, Inc.

Louisiana argued that the district court lacked subject-matter jurisdiction, citing Elam v. Kansas City Southern Railway Co. for the rule that defensive preemption does not create federal jurisdiction. The Fifth Circuit distinguishes that line of cases by invoking Planned Parenthood of Hou. & Se. Tex. v. Sanchez (quoting Shaw v. Delta Air Lines, Inc.) and by characterizing this litigation as “a classic Ex parte Young suit.” The lesson is doctrinal: plaintiffs seeking prospective relief against state officials on Supremacy Clause grounds present a federal question under 28 U.S.C. § 1331, unlike private-party suits or state tort suits where preemption is merely defensive.

6. Takings framework and its application: Cedar Point Nursery v. Hassid, Pa. Coal Co. v. Mahon, Penn Cent. Transp. Co. v. City of New York

For AbbVie’s takings claim, the court uses Cedar Point Nursery v. Hassid to distinguish physical from regulatory takings, and Penn Cent. Transp. Co. v. City of New York (with Pa. Coal Co. v. Mahon) for the multi-factor regulatory-takings test. The court then imports Fitch’s analysis: Act 358 imposes a negative non-interference obligation and does not compel transfers, confiscate title, or force below-ceiling-price sales; even under Penn Central, the economic impact and expectations factors do not rise to a taking.

7. Contracts Clause framework: Sveen v. Melin, Allied Structural Steel Co. v. Spannaus, Energy Rsrvs. Grp., Inc. v. Kan. Power & Light Co., NextEra Energy Cap. Holdings, Inc. v. Lake

AstraZeneca’s Contracts Clause theory is measured under the two-step test described in Sveen v. Melin. The court stops at step one (“substantial impairment”) and distinguishes Allied Structural Steel Co. v. Spannaus, which involved sudden, retroactive, contract-rewriting obligations. The court also relies on the regulated-industry expectations reasoning of Energy Rsrvs. Grp., Inc. v. Kan. Power & Light Co. and its own articulation in NextEra Energy Cap. Holdings, Inc. v. Lake: pharmaceutical manufacturers operate amid pervasive state and federal regulation and cannot claim a reasonable expectation that delivery logistics will be governed exclusively by federal law—especially when the PPAs are silent on delivery.

8. Vagueness doctrine and interpretive tools: United States v. Davis, United States v. Lanier, Coates v. City of Cincinnati, Tex. v. Democratic Party v. Abbott

PhRMA’s challenge is tested against the high bar for civil statutes articulated in Tex. v. Democratic Party v. Abbott and against the general due process definitions in United States v. Lanier and Coates v. City of Cincinnati (with the principle that an “imprecise but comprehensible normative standard” is not void). The court also uses the canon noscitur a sociis to interpret “interfere” in the context of “deny, restrict, prohibit,” narrowing the statute toward obstructionist conduct rather than routine audit inquiries.

9. Intervention when the State is already defending: Hopwood v. Texas, Texas v. United States, Wal-Mart Stores, Inc. v. Texas Alcoholic Beverage Comm'n

For LPCA’s intervention, the court treats Hopwood v. Texas as the controlling analogy: when the State is a party defending a matter of sovereign interest, the State is presumed to represent its citizens’ interests, and a proposed intervenor must show a materially distinct interest and inadequate representation. The court acknowledges Wal-Mart Stores, Inc. v. Texas Alcoholic Beverage Comm'n (associations can sometimes intervene) but holds LPCA failed the “inadequate representation” prong under Texas v. United States because it did not identify any distinct defense or litigation posture Louisiana would not advance.

B. Legal Reasoning

1. Jurisdiction: preemption claims as affirmative Supremacy Clause actions

The court separates “defensive” preemption (insufficient for federal-question jurisdiction under the well-pleaded complaint rule) from affirmative suits for prospective relief against state officials. Characterizing the cases as “classic Ex parte Young” actions, it holds federal-question jurisdiction exists because the federal issue appears on the face of the complaints and because federal courts may enjoin enforcement of allegedly preempted state law.

2. Preemption: presumption against preemption + § 340B silence on delivery

The preemption holding proceeds in a structured way:

• Presumption against preemption: because Act 358 fits within traditional state police powers (public health and consumer protection), the court starts with a strong presumption that Congress did not displace state regulation absent “clear and manifest” intent.
• Field preemption rejected: § 340B is comprehensive about pricing and program integrity but leaves “distribution of drugs to patients” and “the role of pharmacies” unregulated; thus Congress did not “completely oust” state power in this area.
• Conflict preemption rejected: the statute does not make compliance with federal law impossible, nor does it force manufacturers to provide 340B discounts to pharmacies (covered entities purchase and hold title; pharmacies dispense as intermediaries). Enforcement does not collide with HHS’s exclusive enforcement of § 340B because Act 358 addresses a different subject: non-interference with delivery to contract pharmacies.
• Obstacle preemption rejected: Act 358 does not regulate prices “on its face”; it regulates interference with acquisition/delivery. The court also refuses the argument that Congress’s “balance” is upset, reasoning that Congress also balanced federal-state allocation by leaving delivery logistics to the States unless Congress amends § 340B.

3. Takings: non-interference duties are not compelled transfers

The court treats AbbVie’s theory as foreclosed by AbbVie, Inc. v. Fitch. Act 358 imposes a negative duty not to obstruct covered entities’ post-purchase delivery instructions; it does not force new sales beyond § 340B, compel the transfer of property, or deprive manufacturers of the (discounted) compensation § 340B provides. Under a regulatory-takings lens, the court finds insufficient economic impact, limited interference with expectations (contract pharmacies have existed “for decades”), and a strongly public-regarding character of the regulation.

4. Contracts Clause: no substantial impairment of PPAs

AstraZeneca’s claim fails at the threshold because Act 358 does not rewrite or alter its Pharmaceutical Pricing Agreement with HHS. The PPAs are silent on delivery logistics; Act 358 regulates covered entity–contract pharmacy arrangements, to which the manufacturer is not a party in contract. In a pervasively regulated industry, manufacturers cannot reasonably expect state law to remain irrelevant to drug distribution and pharmacy practice.

5. Vagueness: “interfere” is narrowed by context

The court rejects the contention that “interfere” could criminalize (or penalize) ordinary audit communications. Using noscitur a sociis, the opinion reads “interfere” alongside “deny, restrict, prohibit,” concluding the statute targets obstructive conduct related to acquisition and delivery to contract pharmacies, not routine compliance activity. Given the heightened tolerance for imprecision in civil statutes, Act 358 supplies adequate notice.

6. Intervention: state-party presumption requires a distinct defense or inadequate representation

Applying Rule 24(a)(2), the court holds LPCA fails the “inadequate representation” prong. Louisiana is presumed to represent citizens’ interests in defending a statute addressing public health. LPCA’s asserted “more focused” interests (business interests of members) mirror the argument rejected in Hopwood v. Texas: an intervenor must show it will do something materially different in the litigation, not merely add another voice.

C. Impact

• Strengthening state authority over 340B delivery logistics: By reaffirming AbbVie, Inc. v. Fitch and aligning with decisions like Pharm. Rsch. & Mfrs. of Am. v. McClain, the Fifth Circuit further entrenches the view that § 340B’s silence leaves room for state “anti-interference” regulation of contract-pharmacy distribution.
• Litigation posture for manufacturers: The opinion narrows viable federal challenges to these statutes within the Fifth Circuit. Preemption claims face an uphill climb absent congressional amendment to § 340B that expressly regulates delivery or preempts state pharmacy-distribution law.
• Administrative enforcement remains partitioned: The court’s “distinct spheres” analysis suggests future disputes will be channeled: HHS handles core § 340B pricing/ceiling-price complaints and integrity issues; states police interference with delivery to contract pharmacies where § 340B is silent.
• Intervention practice: The intervention reversal provides a practical rule for trade groups and associations: when the State is already defending, intervention as of right requires a concrete showing of divergent interests that affect litigation strategy or the presentation of distinct defenses.

4) Complex Concepts Simplified

• 340B basics: Manufacturers that want Medicaid/Medicare Part B reimbursement must sell certain drugs to “covered entities” at a discounted ceiling price. Covered entities (not pharmacies) buy the drugs; contract pharmacies may dispense them to eligible patients.
• Ex parte Young: A doctrine allowing lawsuits for injunctions/declarations against state officials to stop enforcement of unconstitutional or federally preempted state laws—even though states have sovereign immunity.
• Preemption types:
  • Field preemption: Congress so fully occupies a regulatory area that states have no room to act.
  • Conflict preemption: It’s impossible to comply with both state and federal law, or state law blocks federal objectives.
  • Obstacle preemption: A subtype of conflict preemption focused on whether state law stands as an obstacle to Congress’s goals.
• Physical vs. regulatory takings: A physical taking involves compelled occupation or appropriation; regulatory takings involve restrictions that go “too far” under the Penn Central balancing test.
• Contracts Clause “substantial impairment”: Not every regulation affecting the economic environment impairs a contract; the question is whether the law actually rewrites contractual obligations or defeats reasonable expectations based on the contract’s terms and the regulatory backdrop.
• Void-for-vagueness (civil): A civil law is void only if it is so indefinite that it is “no rule at all.” Some interpretive flexibility is tolerated, especially when context narrows meaning.
• Noscitur a sociis: A word’s meaning is informed by nearby words. Here, “interfere” is read in light of “deny, restrict, prohibit.”

5) Conclusion

The Fifth Circuit’s decision solidifies a practical division of labor in the 340B ecosystem: federal law tightly governs pricing and program integrity, while states may regulate drug distribution and pharmacy practices—including prohibiting manufacturers from obstructing covered entities’ use of contract pharmacies— absent clear congressional displacement. The court further confirms that these anti-interference statutes, as framed, do not amount to takings, do not substantially impair manufacturers’ PPAs, and are not void for vagueness. Finally, the intervention reversal reinforces that, when a State is already defending its statute, would-be intervenors must show more than alignment and enthusiasm; they must show inadequacy of representation through a meaningfully distinct interest or defense.